MISME Syndrome Market
Number of pages: 100 | Report Format: PDF | Published date: May 03, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
6.3% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Treatment and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global MISME syndrome market is expected to register a revenue CAGR of 6.3% during the forecast period.
MISME Syndrome Market Fundamentals
Neurofibromatosis type II [NFII/2 or MISME syndrome (multiple inherited schwannomas, meningiomas, and ependymomas)] is a hereditary condition. It has an autosomal mode of transmission and an incidence of around 1 in 60,000; it grows at a modest mean pace of about 1.2 mm/year. The condition is caused by a genetic deficiency (mutation or one allele depletion) on the long arm of chromosome 22. This gene encodes the tumor-suppressor protein Merlin (schwannoma), which is thought to function in the cell's cytoskeleton-to-plasma membrane link, impacting cell shape, motility, and growth control. The condition is autosomal dominant, with no gender preference. It has a clinical penetrance rate of almost 90%. Schwannomas, meningiomas, and ependymomas are the three forms of tumors observed in NF2, with vestibulocochlear schwannomas on cranial nerve eight being the most prevalent.
NF2 has an autosomal dominant inheritance pattern, which means that a change, also known as a mutation or alteration, occurs in only one copy of the gene. This implies that a parent with an NF2 mutation may pass on a copy of their normal gene or a copy of the altered gene to their children. As a result, a kid with a mutation has a 50% probability of inheriting that mutation. A person's sibling, sister, or father who has a mutation has a 50% chance of having the same mutation.
The global MISME syndrome industry analysis report comprehensively analyzes the market, with the factors that either aid or impede the market growth, such as its drivers, restraints, and opportunities. The research provides insight into the companies that operate in the MISME syndrome market and their efforts to position themselves as key players through expansion strategies and innovations. It also highlights recent developments that contribute to the MISME syndrome market growth. The research also analyzes the impact of the COVID-19 pandemic.
This research is valuable for businesses seeking insights into the market, customers, and competition. The research provides special insights into the segmentation, regions, market size & projection, revenue CAGRs, and other important information that may help clients make the right decisions. The report assembles data from market players and professionals across the industrial value chain. The study also incorporates qualitative and quantitative assessments from industry professionals. Secondary research, surveys and interviews, and statistical modeling are all used in our research to estimate market size and projection. Our reports deliver the most reliable market data because of our specialized research methods.
MISME Syndrome Market Dynamics
Major players are putting more emphasis on research and development of innovative medicines for neurofibromatosis 2. Furthermore, clinical studies are well supported by regulatory authorities, which is expected to propel the global neurofibromatosis 2 market forward. For instance, In June 2022, Recursion Announces the Start of a Phase 2/3 Trial for the Treatment of NF2-Mutated Meningiomas at the Children's Tumor Foundation NF Conference. The study will look at REC-2282, a possibly first-in-disease, orally accessible, central nervous system (CNS) penetrant small molecule histone deacetylase (HDAC) inhibitor, for the treatment of progressive neurofibromatosis type 2 (NF2)-mutated meningiomas.
MISME Syndrome Market Ecosystem
MISME Syndrome Market, by Treatment
MISME Syndrome Market by Treatment
[75675]
Tumor removal surgery is the most widely utilized. Though surgery is the primary treatment for tumors less than 3 cm in size, which has a high rate of complications such as facial nerve weakness, hearing loss, and headache. Although surgical resection of symptomatic tumors is the most common approach to clinically significant lesions, radiation and/or chemotherapy may be recommended in some rare cases to treat disabling ependymomas. However, there are concerns about the additional risks of radiation therapy in a patient with a germline tumor suppressor gene mutation (i.e., someone with NF2), as opposed to a person with an isolated, non-NF2-related tumor.
The market segmentation sections provide the MISME syndrome market outlook in terms of the demarcation of different consumer groups. Market segmentation is the split of an industry into subgroups depending on characteristics such as treatment, and other factors. Market segmentation data helps organizations understand the preferences and distinctive demands of different customer groups and implement targeted marketing strategies. This data additionally helps in identifying potential MISME syndrome market demand opportunities.
MISME Syndrome Market by Region
The region's continuous research approaches for the creation of innovative treatment procedures contribute to the overall market expansion. The National Institute of Neurological Disorders and Stroke (NINDS) conducts research to gain fundamental information about the brain and nervous system to minimize the burden of neurological illness. Ongoing NINDS-sponsored research continues to uncover new genes and molecular pathways that may play a role in tumor suppression or growth caused by NF2.
Asia Pacific is seeing the fastest rate of development due to rapid population expansion, expanding consumer awareness, favorable government regulations, and modernization of medical infrastructure, primarily in emerging nations such as India, China, and Japan. Despite these trends, cases of psychological and emotional trauma due to cosmetic deformity caused by NF2 are common in some developing countries, such as India.
Based on the regions, the global MISME syndrome market is segmented into:
The industry's regional segmentation provides insights into geographic pockets in terms of MISME syndrome industry trends, market size, share, and growth rate. This information helps organizations assess potential growth opportunities in new regional markets, understand competitive threats, and develop localized sales and expansion strategies. This section also offers deeper insights into the regional and country-level MISME Syndrome market overview.
Key Components of the Report
MISME Syndrome Market Competitive Landscape
The global MISME market competitive landscape analysis is performed by gathering and evaluating data about the key competitors, industry trends, and market dynamics. It involves collecting and analyzing data on factors such as products, pricing, geographic reach, customer demographics, marketing tactics, and recent developments. Competitive landscape analysis can help organizations identify present or prospective opportunities and risks in the market.
MISME Syndrome Market Strategic Developments
Reasons To Buy This Report
Key Strengths of Our Report
Target Audience to Benefit from this Report.
Neurofibromatosis type II [NF2 or MISME syndrome (multiple inherited schwannomas, meningiomas, and ependymomas)] is a hereditary condition. It has an autosomal mode of transmission and an incidence of around 1 in 60,000; it grows at a modest mean pace of about 1.2 mm/year.
North America will have the largest MISME syndrome market size during the forecast period from 2023 to 2031.
The revenue CAGR of the global MISME syndrome expected to have 6.3% during the forecast period.
The increasing R&D activities are generating unmet opportunities in the MISME syndrome market.
The growth in the cost of research and development operations in the industry is one of the primary variables acting as a limitation in the global MISME syndrome market.
Different companies concentrate on organic growth strategies such as new launches, product approvals, and other factors like patents and events. Acquisitions and partnerships and collaborations were observed as inorganic growth strategies in the market.
The factors such as research and development and technological advancement are the prime driving factors.
Some of the prominent market players in the global MISME syndrome include AstraZeneca Plc, Novartis, Genentech.
Surgical treatment has the highest share in the global MISME syndrome market.
*Insights on financial performance are subject to the availability of information in the public domain